InvestorMind

TORONTO, May 30, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three months ended March 31, 2018. Key highlights include: First quarter (Q1) 2018 Net Revenues of $4,447,147 increased by 16% versus Q1 2017 Q1 2018 Canadian Pharmaceutical Net Revenues of $3,765,638 increased by 12% versus Q1 2017 and International Pharmaceutical Net Revenues of $565,841 increased by 90% versus Q1 2017 Q1 2018 EBITDA 1 of $1,477,767 increased by 24% versus Q1 2017 Q1 2018 Net Income After Tax (NIAT) of $1,143,130 increased by 27% versus Q1 2017 Q1 2018 NIAT percentage to Net Revenues of 26% compares to 24% in Q1 2017 Q1 2018 Fully Diluted EPS of $0.08 was $0.02 higher than Q1 2017 Fully Diluted EPS of $0.06 Fully Diluted EPS for the Trailing Twelve Months ended March 31, 2018 was $0.38 as compared to $0.29 for the Trailing Twelve Months ended March 31, 2017 As at March 31, 2018, the Company had cash, cash equivalents,...

TORONTO, ONTARIO--(Marketwired - May 25, 2017) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three months ended March 31, 2017. Key highlights include: First quarter (Q1) 2017 Net Revenues of $3,821,262 increased by 1% versus Q1 2016 Q1 2017 Pharmaceutical Net Revenues of $3,652,834 increased by 3% versus Q1 2016 with Canadian Pharmaceutical Net Revenues of $3,354,697 increasing by 2% versus Q1 2016 and International Pharmaceutical Net Revenues of $298,137 increasing by 17% versus Q1 2016 Q1 2017 EBITDA 1 of $1,191,324 decreased by 6% versus Q1 2016 Q1 2017 Net Income After Tax (NIAT) of $901,556 decreased by 5% versus Q1 2016 Q1 2017 NIAT percentage to Net Revenues of 24% compares to 25% in Q1 2016 Q1 2017 Fully Diluted EPS was $0.06 as compared to $0.07 in Q1 2016 Trailing Twelve Months Fully Diluted EPS was $0.29 for the twelve months ended March 31, 2017 as compared to $0.26 for the twelve months en...

TORONTO, ONTARIO--(Marketwired - Mar 15, 2017) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2016. Key highlights include: 2016 Net Revenues of $17,922,270 increased by 16% versus 2015  Fourth quarter (Q4) 2016 Net Revenues of $5,009,668 a record quarter for the Company, increased by 30% versus Q4 2015  2016 Pharmaceutical Net Revenues of $16,663,159 increased by 16% versus 2015  Q4 2016 Pharmaceutical Net Revenues of $4,922,773 increased by 30% versus Q4 2015  2016 EBITDA 1  of $5,900,080 increased by 15% versus 2015  Q4 2016 EBITDA 1  of $1,591,047 increased by 58% versus Q4 2015  2016 Net Income After Tax (NIAT) of $4,309,505 increased by 14% versus 2015  2016 NIAT percentage to Net Revenues was 24% as compared to 24% in 2015  Q4 2016 NIAT of $1,094,822 increased by 44% versus Q4 2015  Q4 2016 NIAT percentage to Net Re...